NCT03194061

Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck Cancer

Hypofractionated Radiotherapy and Concurrent Cisplatin for Locally Advanced Head and Neck Cancer: A Feasibility Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Barretos Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the feasibility of hypofractionated radiation therapy and concomitant chemotherapy with cisplatin for locally advanced head and neck cancer in a high volume brazilian center.

Detailed description

To evaluate if concomitant cisplatin and hypofractionated radiation therapy wold be feasible in a brazilian population. Patients eligibility criteria: older than 18 years old Biopsy proven squamous cell carcinoma of oropharynx, larynx and hypopharynx. Stage III an IV, with no distant metastasis. ECOG performance status 0-2. Adequate renal and liver function. Good status for radical treatment Treatment considered feasible if: 1. Patient receive at least 90% of radiation dose (18 of 20 fractions of 275cGy) 2. Patients receive at least 3 of 4 weekly cycles of cisplatin (35mg/m2) 3. Treatment length up to 35 days. 4. Grade 4 toxicity lower than 25%

Conditions

• Radiotherapy; Complications

Interventions

Type	Name	Description
RADIATION	Hypofractionated Radiotherapy	20 fractions of 275cGy 5 days/week
DRUG	Weekly cisplatin	Concomitant weekly cisplatin 35mg/m2 x 4 weeks

Timeline

• Start date: 2015-01-01
• Primary completion: 2019-08-31
• Completion: 2019-08-31
• First posted: 2017-06-21
• Last updated: 2018-01-19